Early neurological deterioration (END) following ischaemic stroke is a serious event with
manageable causes in only a fraction of patients. The incidence, causes and predictors of …

Stroke occurs when a cerebral blood vessel is blocked or ruptured, and it is the major cause
of death and adult disability worldwide. Various pharmacological agents have been …

Background and Purpose—The authors present an overview of the current evidence and
management recommendations for evaluation and treatment of adults with acute ischemic …

Background and Purpose—The optimal management of blood pressure (BP) in acute stroke
remains unclear. For ischemic stroke treated with intravenous thrombolysis, current …

Background Thrombolysis with intravenous alteplase is the only approved treatment for
acute ischaemic stroke. After alteplase-induced recanalisation, reocclusion occurs in 14 …

Epidemiologic studies have correlated elevated plasma fibrinogen (hyperfibrinogenemia)
with risk of cardiovascular disease and arterial and venous thrombosis. However, it is …

Tirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly
inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi …

Tissue plasminogen activator (tPA) is the only therapeutic agent approved to treat patients
with acute ischemic stroke. The clinical benefits of tPA manifest when the agent is …

Background and Purpose—We investigated whether early initiation of tirofiban, a
glycoprotein IIb/IIIa antagonist, is safe, can reduce the risk of reocclusion, and improve …

Background and Purpose—We sought to evaluate how accurately length and volume of
thrombotic clots occluding cerebral arteries of patients with acute ischemic stroke can be …